Teleflex acquired NeoTract in 2017, including a minimally invasive technology called UroLift System for the treatment of BPH. Credit: Boris7.

Teleflex unit NeoTract has reported 12-month results from the prospective MedLift Study of its UroLift System to treat benign prostatic hyperplasia (BPH) patients with an obstructive median lobe.

The MedLift Study was conducted to validate the safety and efficacy of the UroLift System treatment.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Findings showed significant improvements in international prostate symptom score (IPSS), peak flow rate (Qmax) and quality of life (QoL).

Mean IPSS was found to have improved by at least 13.5 points from baseline, while mean Qmax improvement ranged from 90% to 129% and QoL improvements were seen at three, six and 12 months.

Outcomes were found to be consistent with those of the five-year pivotal L.I.F.T study of UroLift.

These latest results were published in the Nature Publishing Group’s Prostate Cancer and Prostatic Diseases journal.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"Data from this study has helped the UroLift System become a standard of care treatment for patients with BPH."

The data also supported the recent US Food and Drug Administration (FDA) clearance allowing UroLift System treatment for BPH symptoms in patients with an obstructive median lobe.

Teleflex Interventional Urology business unit president Dave Amerson said: “The MedLift Study provides additional evidence of the UroLift System’s utility for the treatment of a broad range of men with BPH, allowing more patients to benefit from this minimally invasive technology.

“The data from this study, among the many supportive findings from a number of clinical and real-world studies of the UroLift System, have helped the UroLift System become a standard of care treatment for patients with BPH.”

Teleflex acquired NeoTract in 2017 for approximately $1.1bn. NeoTract’s UroLift System is a minimally invasive technology indicated for lower urinary tract symptoms caused due to BPH.

The device is permanently implanted during a minimally invasive transurethral outpatient procedure.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact